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Objectives: It is controversial whether sodium glucose transporter (SGLT) 2 inhibitors increase glucagon secretion via direct inhibition of SGLT2
in pancreatic a cells. The role of SGLT1 in a cells is also unclear. We aimed to elucidate these points that are important not only for basic research
but also for clinical insight.
Methods: Plasma glucagon levels were assessed in the high-fat, high-sucrose diet (HFHSD) fed C57BL/6J mice treated with dapagliﬂozin or
canagliﬂozin. RT-PCR, RNA sequence, and immunohistochemistry were conducted to test the expression of SGLT1 and SGLT2 in a cells. We also
used aTC1 cells and mouse islets to investigate the molecular mechanism by which SGLT1 modulates glucagon secretion.
Results: Dapagliﬂozin, but not canagliﬂozin, increased plasma glucagon levels in HFHSD fed mice. SGLT1 and glucose transporter 1 (GLUT1),
but not SGLT2, were expressed in aTC1 cells, mouse islets and human islets. A glucose clamp study revealed that the plasma glucagon increase
associated with dapagliﬂozin could be explained as a response to acute declines in blood glucose. Canagliﬂozin suppressed glucagon secretion by
inhibiting SGLT1 in a cells; consequently, plasma glucagon did not increase with canagliﬂozin, even though blood glucose declined. SGLT1 effect
on glucagon secretion depended on glucose transport, but not glucose metabolism. Islets from HFHSD and db/db mice displayed higher SGLT1
mRNA levels and lower GLUT1 mRNA levels than the islets from control mice. These expression levels were associated with higher glucagon
secretion. Furthermore, SGLT1 inhibitor and siRNA against SGLT1 suppressed glucagon secretion in isolated islets.
Conclusions: These data suggested that a novel mechanism regulated glucagon secretion through SGLT1 in a cells. This ﬁnding possibly
explained the distinct effects of dapagliﬂozin and canagliﬂozin on plasma glucagon levels in mice.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords Alpha cell; Diabetes; Sodium glucose cotransporter; SGLT; Phloretin; Sotagliﬂozin1. INTRODUCTION
Pancreatic a cells secrete glucagon, which controls blood glucose
levels. In patients with type 1 or type 2 diabetes mellitus, hypergly-
cemia is often associated with hyperglucagonemia [1]. High levels of
glucagon have been shown to contribute to diabetic hyperglycemia
[2,3]. Thus, suppressing glucagon secretion could be a novel strategy
for treating diabetes [4,5]. However, the mechanism underlying
impaired glucagon secretion is not fully understood. Glucose is known
to be a direct regulator of glucagon secretion [6e8]. Glucose uptake
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www.molecularmetabolism.compassive glucose transporter GLUT1 [9]; however, a recent report
described the expression of sodium glucose cotransporters 1 and 2
(SGLT1 and SGLT2) in a cells [10]. SGLT1 and SGLT2 are active
glucose transporters; they take up glucose against a concentration
gradient through energy derived from sodium gradients [11]. In the
kidney, these transporters are responsible for glucose reabsorption.
Previously, SGLT2 was thought to be speciﬁcally expressed in the
kidney; SGLT2 inhibitors were approved as clinical therapeutic agents
for diabetes, because they promote urinary glucose excretion.
Importantly, in clinical trials, when patients with type 2 diabetes were
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Original Articleempagliﬂozin, plasma glucagon levels increased, which enhanced
hepatic glucose production [12,13]. It remains controversial whether
these results were caused by a direct inhibition of SGLT2 in a cells or
by a compensative mechanism triggered by declining blood glucose
levels [12,14e16]. Bonner et al. reported that SGLT2 was expressed in
a cells, and dapagliﬂozin increased plasma glucagon levels by
inhibiting SGLT2 in a cells [10]. Conversely, a recent report showed
that SGLT2 expression levels were nearly undetectable in aTC1 cells
[17]. Also, perfused islets isolated from SGLT2-knockout mice did not
differ from control islets in glucagon secretion under high or low
glucose conditions [18]. Moreover, another SGLT2 inhibitor, canagli-
ﬂozin, was reported to have no effect on plasma glucagon levels in
diabetic rats [19].
On the other hand, SGLT1 is expressed in the small intestine and kid-
neys. This transporter is known to be associated with GLP-1 secretion
[20e24]. SGLT1 in the ventromedial hypothalamus was also reported to
play a signiﬁcant role in sensing low plasma glucose [25].
Based on those ﬁndings, we hypothesized that SGLT1 in a cells might
be associated with the regulation of glucagon secretion. In addition, we
reasoned that the actions of SGLT2 inhibitors on SGLT1 might explain
their different effects on glucagon. Compared to dapagliﬂozin, which is
a speciﬁc SGLT2 inhibitor, canagliﬂozin could also inhibit SGLT1,
although its potency for SGLT1 is much lower than its potency for
SGLT2 [26]. Thus, we expected that canagliﬂozin might affect
glucagon secretion differently from other highly speciﬁc SGLT2 in-
hibitors. The present study aimed to investigate these hypotheses.
For the past several decades, glucagon research has been hindered by
the lack of speciﬁc, sensitive assay systems. In fact, Bak et al. reported
that, of eight different commonly used glucagon assay kits, none
provided sufﬁciently sensitive and speciﬁc measurements [27].
Therefore, we recently developed a novel, accurate analytical method
for measuring glucagon using liquid chromatography and mass
spectrometry (LC-MS/MS). In comparing glucagon levels detected with
various assays against measurements with LC-MS/MS, we revealed
that the Mercodia sandwich ELISA was much more accurate than the
conventional RIA kits [28]. Most previous evaluations of the effects of
SGLT2 inhibitors on plasma glucagon levels were conducted with
conventional RIA kits [12,13,19]. Therefore, in the present study, we
investigated the effects of SGLT2 inhibitors using Mercodia sandwich
ELISA.
2. MATERIAL AND METHODS
2.1. Animal studies
All experimental procedures were performed according to the Guide for
the Care and Use of Laboratory Animals, of the Science Council of
Japan. The study was approved by the Animal Experiment Committee
of Gunma University. All animals were maintained in a speciﬁc
pathogen-free space under a 12-h light/dark regimen. We purchased
7-week old C57BL/6J male mice and diabetic (db/db) male mice
(Charles River Laboratories, Japan). C57BL/6J mice were randomly
assigned to consume normal chow (CE-2, CLEA, Japan) or a high-fat,
high-sucrose diet (HFHSD) containing 20% sucrose, at the age of 8-
weeks. The total energy in the HFHSD (Oriental Yeast, Japan) con-
sisted of protein (17.2%), fat (54.5%), and carbohydrate (28.3%).
Water was provided ad libitum. None of the animals included in the
data analyses displayed any health impairments.
SGLT2 inhibitors were suspended in a 0.5% methyl cellulose solution
(Wako, Japan). Food was removed from the cages before drug
administration. At time ¼ 0 min, dapagliﬂozin (3 and 10 mg/kg;
Cayman Chemical Company, USA), canagliﬂozin (10 and 30 mg/kg;2 MOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. TMitsubishi Tanabe Pharma Corporation, Japan), or vehicle was
administered orally to the animals via a stomach tube, at a volume of
10 ml/g. Glucose levels of all the blood samples were measured with a
glucometer (Sanwa Kagaku, Japan). Plasma glucagon, insulin, and
active GLP-1 levels were measured using blood samples obtained at
t ¼ 4 h with a Glucagon sandwich ELISA (Mercodia, Sweden), an
insulin ELISA (Shibayagi, Japan), and an active GLP-1 ELISA (Shi-
bayagi, Japan), respectively. Urine was collected in metabolic cages
over a 4 h period after drug administration. Urine glucose was analyzed
with a Glucose C II Test (Wako, Japan).
2.2. Glucose clamp study
C57BL/6J mice fed HFHSD (20-week old males) underwent aseptic
surgery 1 week before the clamp studies. Mice were catheterized at
the left common carotid artery and the right jugular vein. Clamps were
performed on unrestrained, conscious mice. Food was removed at the
start of drug administration. The glucose clamp was initiated at
t ¼ 30 min. Blood glucose levels were maintained at 8.3e13.8 mmol/
L during the 210 min clamps, by monitoring blood glucose every
10 min and infusing 40% dextrose, when necessary. Mice that
received vehicle were infused with saline (controls). The glucose
infusion rate (GIR) was expressed in mmol kg BW1 min1. Blood
samples were collected at the end of the study to determine plasma
glucagon.
2.3. aTC1 cells and mouse islets
aTC1 clone 6 cells (CRL-2934, ATCC, USA) were cultured in D-MEM
medium supplemented with 10% FBS, 1% penicillin/streptomycin,
15 mM HEPES, 0.1 mM non-essential amino acids, and 16.7 mM
glucose, in a humidiﬁed atmosphere, containing 5% CO2 as described
[7,10,17]. Mouse islets were isolated as described [29]. Brieﬂy, mice
were anesthetized and killed by cervical dislocation. Islets were puri-
ﬁed from mice with collagenase (C7657, Sigma, Japan) digestion and
subsequent centrifugation over a Histopaque gradient.
2.4. RT-PCR, quantitative PCR, and high-throughput RNA-
sequencing
Total RNA was isolated from aTC1 cells, mouse islets, and mouse
kidneys with the RNAiso Plus kit (Takara, Japan). Isolated RNA was
reverse transcribed to cDNA with the Improm II Reverse Transcription
System (Promega, Japan). cDNA samples (1 mg) were subjected to RT-
PCR, with a PCR Kit (TaKaRa, Japan), or quantitative PCR (qPCR), with
the Applied Biosystems ViiA7 Real-Time PCR System (Life Technol-
ogies, Japan) and the PowerUp SYBR Green Master Mix (Fisher
Scientiﬁc, USA). The speciﬁc primer sequences were listed in
Supplementary Table 1. Target mRNA expression levels were evalu-
ated relative to mouse b-actin mRNA levels (control gene). High-
throughput RNA sequencing was performed by DNA Chip Research,
Inc., Tokyo, Japan.
2.5. Immunohistochemistry
C57BL/6J mice fed HFHSD (22-week old males) were anesthetized
and perfused transcardially with ice-cold, 0.05 M phosphate-buffered
saline (pH 7.4), followed by 4% paraformaldehyde (PFA) for ﬁxation.
The pancreas and kidney were dissected and ﬁxed in 4% PFA at 4 C.
Samples were frozen in OCT compound and sectioned in 5-mm thick
slices. Human tissue sections were purchased (BioChain Institute Inc.,
USA). For immunostaining, we used rabbit polyclonal anti-SGLT1
(ab14685; abcam, Japan), rabbit polyclonal anti-SGLT2 (ab85626;
abcam, Japan), guinea pig polyclonal anti-insulin (A0564; Dako,
Japan), and mouse monoclonal anti-glucagon (ab10988; abcam,his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Japan) antibodies. We visualized immune complexes with FITC- or
CY3-conjugated secondary antibodies.
2.6. siRNA transfection
For siRNA-silencing experiments, mouse islets and aTC1 cells were
transfected with scrambled control or the mouse Slc5a1 Silencer
Select siRNA (s73953, Ambion, Life Technologies, Japan). Trans-
fections were performed with Lipofectamine RNAiMAX (13778, Invi-
trogen Life Technologies, Japan). The knock-down efﬁciency was
evaluated at 48 h after transfection with a quantitative RT-PCR anal-
ysis. At 96 h after transfection, cells were transferred to new plates for
secretion experiments.
2.7. Glucagon secretion experiment
Ten size-matched mouse islets or aTC1 cells were treated with or
without various concentrations of dapagliﬂozin, canagliﬂozin, sotagli-
ﬂozin (Chemscene, USA), or phloretin (Wako, Japan). The glucoseFigure 1: Plasma glucagon levels were increased with dapagliﬂozin and unaltered w
the changes in blood glucose at 4 h after administration of the indicated doses of vehicle,
glucose excretion in HFHSD mice collected at 4 h after treatment with the indicated doses o
GLP-1 levels in HFHSD mice treated with the indicated doses of vehicle, dapagliﬂozin, or ca
or between the indicated groups.
MOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. This is an open acc
www.molecularmetabolism.comconcentration was 5 mM, unless otherwise stated. Supernatants were
assayed for glucagon with the sandwich ELISA. Results were
normalized to total protein levels. High methyl-a-D-glucopyranoside
(aMG) condition (100 mM) was experimented as previously described
[20,21]. Osmolarity was maintained in experiments with high aMG by
reducing the NaCl concentration to 95 mM. Control solutions for these
experiments contained 100 mM mannitol.
2.8. Calcium imaging
Intracellular calcium concentration [Ca2þ]i was measured by ratio-
metric fura-2 ﬂuorescence imaging, as previous described [21,30].
2.9. Statistical analysis
Data are presented as the mean  SE. The signiﬁcance of differences
was assessed with the Student’s t-test or ANOVA followed by post hoc
tests (Dunnett’s or TukeyeKramer’s test) for multiple comparisons. p-
values < 0.05 were considered statistically signiﬁcant.ith canagliﬂozin in HFHSD fed mice. (A) Time course of blood glucose levels and (B)
dapagliﬂozin, or canagliﬂozin in HFHSD mice, at 20-weeks of age. (n ¼ 11). (C) Urinary
f dapagliﬂozin or canagliﬂozin. (n ¼ 11). (D) Plasma glucagon, (E) insulin, and (F) active
nagliﬂozin. (n ¼ 11). Data are the mean  SE *p < 0.05, **p < 0.01; vs. vehicle group
ess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Original Article3. RESULTS
3.1. Dapagliﬂozin, but not canagliﬂozin, increased plasma
glucagon in HFHSD mice
Dapagliﬂozin and empagliﬂozin were reported to increase plasma
glucagon levels in patients with type 2 diabetes [12,13]; in contrast,Figure 2: SGLT1, but not SGLT2, is expressed in aTC1 cells, mouse islets, and h
expression, in aTC1 cells, mouse islets, and mouse kidney. (B) Quantitative real-time RT-
cells, mouse islets, and mouse kidney (n ¼ 3 per group). Data are the mean  SD. (C) Dire
and mouse kidney. (DeG) Representative images of immunostained tissue sections of mo
kidney (G) for SGLT1 (red), SGLT2 (red), glucagon (green), and insulin (green). Yellow indic
Scale bars ¼ 20 mm.
4 MOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. Tcanagliﬂozin did not alter plasma glucagon levels in rats [19]. However,
in those studies glucagon was measured with conventional RIA kits,
which are unreliable. Therefore, we ﬁrst tested the effects of dapa-
gliﬂozin and canagliﬂozin on plasma glucagon levels in HFHSD mice
with the sandwich ELISA system, which we had recently conﬁrmed
was more accurate than the conventional RIA for glucagonuman islets. (A) RT-PCR analyses for SGLT1, SGLT2, GLUT1, glucagon, and b-actin
PCR analyses for SGLT1 and SGLT2 expression, relative to b-actin expression in aTC1
ct sequencing of whole RNA samples for SGLT2 expression in aTC1 cells, mouse islets,
use pancreas (D), human type 2 diabetic pancreas (E), mouse kidney (F), and human
ates co-localization of SGLT1 and SGLT2 with glucagon or insulin. Blue indicates DAPI.
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Neither dapagliﬂozin nor canagliﬂozin increased plasma glucagon
levels under constant blood glucose conditions in HFHSD mice. Measurements
taken during glucose clamp studies performed for 4 h after treatment with vehicle,
10 mg/kg dapagliﬂozin, or 10 mg/kg canagliﬂozin in HFHSD mice at 20-weeks of age.
(A) Time course of blood glucose; (B) plasma glucagon measured at 4 h after drug
administration; (C) time course of glucose infusion rates with area under the curve
(AUC). Data are the mean  SE (n ¼ 7 or 8 mice in each group). *p < 0.05 vs.
canagliﬂozin-treated group.measurements [28]. We found that 10 mg/kg dapagliﬂozin and 10 mg/
kg canagliﬂozin lowered blood glucose levels to the same degree
(Figure 1A,B). Nevertheless, this dose of canagliﬂozin induced less
urinary glucose excretion than dapagliﬂozin (Figure 1C). On the other
hand, the urinary glucose excretion induced by 30 mg/kg canagliﬂozin
was almost same as that induced by 10 mg/kg dapagliﬂozin
(Figure 1C). Although 10 mg/kg dapagliﬂozin signiﬁcantly increased
plasma glucagon levels compared to control mice, neither 10 mg/kg
nor 30 mg/kg canagliﬂozin increased plasma glucagon levels
(Figure 1D). Plasma insulin levels were slightly reduced by 10 mg/kg
canagliﬂozin (Figure 1E), but plasma GLP-1 levels were not affected by
either SGLT2 inhibitor (Figure 1F). We obtained similar results in a
diabetic mouse model (db/db mice; Supplementary Figs. 1AeD).
However, neither dapagliﬂozin nor canagliﬂozin increased plasma
glucagon levels in chow-fed, wild-type mice (Supplementary
Figs. 1EeH). Thus, the effect of dapagliﬂozin on glucagon appeared
to be speciﬁc for the diabetic condition.
3.2. SGLT1, but not SGLT2, is expressed in aTC1 cells, mouse
islets, and human islets
Recently, Bonner et al. reported that SGLT1 and SGLT2 were
expressed in pancreatic a cells. They showed that dapagliﬂozin
increased plasma glucagon levels by directly inhibiting SGLT2 in a
cells [10]. However, SGLT2 was previously thought to be expressed
speciﬁcally in renal tubule cells. Therefore, we tested our aTC1 cells
and mouse islets to determine whether SGLT1, SGLT2, and GLUT1
were expressed. RT-PCR revealed that SGLT1 and GLUT1 were
expressed, but SGLT2 was not expressed, in both aTC1 cells and
mouse islets (Figure 2A). We conﬁrmed these results with quantitative
real-time RT-PCR (Figure 2B). Furthermore, direct sequencing of whole
RNA isolated from aTC1 cells and mouse islets revealed that SGLT2
sequences were rarely detected in RNA reads, although they were
abundantly detected in RNA isolated from the kidney (Figure 2C). These
results indicated that pancreatic a cells do not express SGLT2 and
that, apparently, dapagliﬂozin’s effects on plasma glucagon were not
mediated by direct SGLT2 inhibition in a cells. On the other hand,
immunostaining showed that SGLT1 was expressed speciﬁcally in a
cells, but not in b cells, in mouse islets (Figure 2D). Interestingly, not
all, but some a cells expressed SGLT1, suggesting heterogeneity
among a cells (Figure 2D). We also observed similar expression pat-
terns in human pancreatic sections (Figure 2E). As controls, both
SGLT1 and SGLT2 were detected in mouse and human kidney sections
(Figure 2F,G).
3.3. Neither dapagliﬂozin nor canagliﬂozin increased plasma
glucagon levels under constant blood glucose conditions in HFHSD
mice
As described above, the glucagon-increasing effect of dapagliﬂozin
was not mediated by a direct mechanism in a cells. Therefore, we
hypothesized that dapagliﬂozin might increase glucagon through an
indirect mechanism that sensed acute declines in blood glucose levels.
To test this hypothesis, we performed a glucose clamp experiment in
HFHSD mice. We reasoned that, if dapagliﬂozin’s effect was mediated
by a compensation mechanism, which responded to an acute decline
in blood glucose, then, under constant blood glucose clamp conditions,
dapagliﬂozin would not increase plasma glucagon levels. As shown in
Figure 3A,B, neither 10 mg/kg dapagliﬂozin nor 10 mg/kg canagliﬂozin
increased plasma glucagon levels under clamp conditions. Importantly,
the glucose infusion rate during the glucose clamp was higher in
dapagliﬂozin-treated mice than in canagliﬂozin-treated mice
(Figure 3C). This ﬁnding was consistent with former results thatMOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. This is an open acc
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than in canagliﬂozin-treated mice (Figure 1C). These results suggested
that dapagliﬂozin increased plasma glucagon through a compensation
mechanism that sensed acute declines in blood glucose. In other
words, despite the fact that 10 mg/kg dapagliﬂozin induced greater
urinary glucose excretion than 10 mg/kg canagliﬂozin, these two
SGLT2 inhibitors had comparable blood glucose-lowering effects,
possibly due to the compensatory glucagon secretion induced by
dapagliﬂozin, but not canagliﬂozin.
3.4. Canagliﬂozin suppressed glucagon secretion by inhibiting
SGLT1 in aTC1 cells and mouse islets
We next addressed the question of why a compensatory increase in
plasma glucagon was not observed in canagliﬂozin-treated mice,
despite the fact that canagliﬂozin and dapagliﬂozin induced the same
degree of decline in blood glucose. We noted that the selectivities for
SGLT2 are different between dapagliﬂozin and canagliﬂozin (canagli-
ﬂozin is less selective for SGLT2 than dapagliﬂozin) and that SGLT1 is
indeed expressed in a cells (Figure 2A, B, D, E). Therefore, we hy-
pothesized that canagliﬂozin, a SGLT2/low-potency-SGLT1 inhibitor,
might suppress glucagon secretion by inhibiting SGLT1 in a cells;
canagliﬂozin did not increase plasma glucagon levels in HFHSD mice or
db/db mice, even under conditions of declining blood glucose. To test
this hypothesis, we incubated aTC1 cells with canagliﬂozin oress article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
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clinical daily dose, produced a peak plasma concentration of 7.8e
10 mM in humans [26,31]. Therefore, we tested two concentrations, 2
and 20 mM. After 2 h incubations, both 2 and 20 mM canagliﬂozin,
signiﬁcantly decreased glucagon secretion from aTC1 cells
(Figure 4A). In contrast, dapagliﬂozin did not affect glucagon secretion
at either 2 or 20 mM, but 200 mM dapagliﬂozin signiﬁcantly inhibited
glucagon secretion (Figure 4A). Based on the fact that 20 mg dapa-
gliﬂozin, a double clinical daily dose, was known to produce peak
plasma concentrations of only 0.7 mM in humans [26,32], we assumedFigure 4: Canagliﬂozin and sotagliﬂozin suppressed glucagon secretion by inhibiti
during 2 h incubations with or without dapagliﬂozin, canagliﬂozin or KCl (60 mM) at the ind
islets during 2 h incubations without or with 2 mM dapagliﬂozin or canagliﬂozin under 1
during 2 h incubations with or without 20 mM canagliﬂozin or sotagliﬂozin (n ¼ 6). (D) Rela
siRNA (n ¼ 6e8). (E) Glucagon secretion from aTC1 cells transfected with SGLT1 siRNA o
Data are the mean  SE. *p < 0.05, **p < 0.01; vs. respective control. N.S.; not signiﬁ
6 MOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. Tthat 200 mM dapagliﬂozin was an overdose compared to the clinical
dose. Consistent with these results, 2 mM canagliﬂozin, but not 2 mM
dapagliﬂozin, inhibited glucagon secretion in isolated mouse islets in
both 1 mM and 5 mM glucose conditions (Figure 4B). In addition, a
non-selective SGLT inhibitor, sotagliﬂozin, which inhibits both SGLT2
and SGLT1, also signiﬁcantly inhibited glucagon secretion in aTC1
cells (Figure 4C).
To investigate further whether canagliﬂozin suppression of glucagon
was mediated by SGLT1 inhibition, we knocked down SGLT1 in aTC1
cells. Cells transfected with SGLT1-siRNA displayed 80% reductions inng SGLT1 in aTC1 cells and mouse islets. (A) Glucagon secretion from aTC1 cells
icated concentrations (n ¼ 5e6). (B) Glucagon secretion from 10 size-matched mouse
mM or 5 mM glucose conditions (n ¼ 7e10). (C) Glucagon secretion from aTC1 cells
tive SGLT1 mRNA expression in aTC1 cells transfected with SGLT1 siRNA or scrambled
r scrambled siRNA, then incubated for 2 h with or without 20 mM canagliﬂozin (n ¼ 6).
cant.
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SGLT1 mRNA levels (Figure 4D) and exhibited signiﬁcantly reduced
glucagon secretion (Figure 4E). Importantly, canagliﬂozin did not
further suppress glucagon secretion in SGLT1-knock-down aTC1 cells
(Figure 4E). This result suggested that canagliﬂozin directly sup-
pressed glucagon secretion by inhibiting SGLT1 in a cells.
3.5. Canagliﬂozin suppressed glucagon secretion depending on
glucose transport, but not glucose metabolism
Because SGLT1 is a sodium/glucose cotransporter, we next asked
which inhibition of glucose transport or glucose metabolism was
pivotal for the effect of canagliﬂozin. In the absence of glucose, can-
agliﬂozin had no effect on glucagon secretion in aTC1 cells (Figure 5A).
Importantly, when glucose was replaced with aMG, a non-
metabolizable glucose analog as well as a speciﬁc substrate for
SGLTs [20,24], canagliﬂozin could suppress glucagon secretion. In
contrast, when glucose was replaced to mannitol, a non-transportableFigure 5: Canagliﬂozin suppressed glucagon secretion depending on glucose
transport, but not glucose metabolism. (A) Glucagon secretion from aTC1 cells
incubated with or without canagliﬂozin, in the presence or absence of 5 mM glucose
(n ¼ 8). (B) Glucagon secretion from aTC1 cells incubated with or without canagliﬂozin
in the presence or absence of 100 mM aMG or 100 mM mannitol instead of glucose
(n ¼ 4e6). The white, gray, and black bars indicate 0, 2, and 20 mM canagliﬂozin,
respectively. Data are the mean  SE. *p < 0.05, **p < 0.01; vs. respective control.
N.S.; not signiﬁcant.
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These results suggested that canagliﬂozin’s effect did not depend on
the metabolic effect of glucose but depended on substrate transport.
Thus, canagliﬂozin suppressed glucagon secretion by inhibiting
SGLT1-mediated sodium/glucose cotransport.
3.6. Canagliﬂozin suppressed aMG-induced intracellular Ca2þ
increase in aTC1 cells
Because it has been reported that SGLT1-mediated sodium/glucose
cotransport depolarizes the membrane and stimulates Ca2þ entry,
which results in enhancing GLP-1 secretion in intestinal cells [20e24],
we assessed intracellular calcium concentrations in aTC1 cells. As
shown in Figure 6A, aMG increased [Ca2þ]i, that was inhibited by
canagliﬂozin but not dapagliﬂozin (Figure 6BeD). Interestingly, this
inhibition was canceled as soon as canagliﬂozin removed (Figure 6E,F).
These results suggested that canagliﬂozin suppresses glucagon
secretion by inhibiting Ca2þ entry in a cells.
3.7. Islets from HFHSD mice and db/db mice expressed higher
SGLT1 and lower GLUT1 mRNA levels, which was associated with
increased glucagon secretion, compared to controls
We next investigated the physiological relevance between the mRNA
levels of SGLT1/GLUT1 and the glucagon secretion levels observed in
diabetic mice. As shown in Figure 7A, SGLT1 mRNA levels increased,
and GLUT1 mRNA levels decreased, in aTC1 cells cultured in high
glucose conditions. Consistent with these results, we observed higher
SGLT1 mRNA levels and lower GLUT1 mRNA levels in the islets of
HFHSD mice (Figure 7B) and db/db mice (Figure 7C), compared to the
islets of control mice. Importantly, the higher SGLT1 and lower GLUT1
mRNA levels were associated with higher glucagon secretion from
islets of HFHSD mice (Figure 7D) and db/db mice (Figure 7E) compared
to control islets. These results suggested that SGLT1 and GLUT1 might
play important roles in the regulation of glucagon secretion in a cells.
To investigate the roles of SGLT1 and GLUT1 in the regulation of
glucagon secretion in mouse islets, we treated the islets with the non-
selective SGLT inhibitor, sotagliﬂozin, or the GLUT inhibitor, phloretin.
Glucagon secretion in mouse islets was decreased by 70% with
sotagliﬂozin, and it was increased by 1.7-fold with phloretin
(Figure 7F). We also found that a w40% reduction in SGLT1 mRNA
levels using siRNA was associated with a 50% reduction in glucagon
secretion (Figure 7G). These results indicated that SGLT1 is an
important regulator of glucagon secretion in a cells; thus, increases in
SGLT1 expression might explain the elevated glucagon secretion
observed in diabetic mice.
4. DISCUSSION
The present study described ﬁve novel ﬁndings; (i) dapagliﬂozin, but
not canagliﬂozin, increased plasma glucagon levels in diabetic mice;
(ii) SGLT1, but not SGLT2, was expressed in pancreatic a cells in
mouse and human; (iii) dapagliﬂozin-induced increases in plasma
glucagon were driven by a compensatory mechanism that responded
to acute declines in blood glucose; (iv) canagliﬂozin suppressed
glucagon secretion in aTC1 cells by inhibiting SGLT1 in a glucose
transport-dependent and intracellular Ca2þ increase-dependent
manner; and (v) increased SGLT1 mRNA levels in a cells was asso-
ciated with higher glucagon secretion in diabetic models.
Consistent with previous reports [10,12], our study showed that
dapagliﬂozin increased plasma glucagon levels in HFHSD mice and db/
db mice. Bonner et al. proposed that SGLT2 was expressed in aTC1
cells, mouse islets, and human islets, and that dapagliﬂozin increasedess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 6: Canagliﬂozin suppressed aMG-induced [Ca2D]i increase in aTC1 cells. (AeC) Representative tracing of 100 mM aMG-induced [Ca
2þ]i increase (A), with 2 mM
dapagliﬂozin (B), or 2 mM canagliﬂozin (C) in aTC1 cells, as indicated by assessing ratios of Fura-2 emission at 340 nm and 380 nm. (D) Quantiﬁcation of the change of 100 mM
aMG-induced [Ca2þ]i increases (n ¼ 30), with 2 mM dapagliﬂozin (n ¼ 38), or 2 mM canagliﬂozin (n ¼ 16). (E, F) Representative tracing (E) and quantiﬁcation of the change (F) of
100 mM aMG-induced [Ca2þ]i increases before and after the removal of 2 mM canagliﬂozin (n ¼ 34). The data of quantiﬁcation of the change of [Ca2þ] i increases were calculated
by dividing the peak [Ca2þ] i by the basal [Ca
2þ] i. The numbers above each bar indicate the number of cells that responded over the number of cells examined. Cells that increased
[Ca2þ] i more than 5% compared to the basal [Ca
2þ] i were considered to be responded. Data are the mean  SE. *p < 0.05, **p < 0.01; vs. respective control.
Original Articleglucagon secretion by directly inhibiting SGLT2 in a cells [10]. How-
ever, we did not detect SGLT2 expression in aTC1 cells, mouse islets
and human islets (Figure 2AeE). Our results are supported by recent
report, which discloses single cell transcriptome proﬁling of human
pancreatic islets in healthy and type 2 diabetes patients [33]. These
data sets also show SLC5A2 (which encodes SGLT2) is rarely
detectable in pancreatic a cells. Furthermore, glucagon secretion was
not stimulated by dapagliﬂozin in aTC1 cells or mouse islets
(Figure 4A,B). Therefore, our results suggested that it was unlikely that
dapagliﬂozin’s effect on plasma glucagon was mediated by direct in-
hibition of SGLT2 in a cells. Alternatively, based on our glucose clamp
experiment results, we proposed that dapagliﬂozin might trigger a
mechanism that compensated for acute declines in blood glucose
levels, and this mechanism could account for the increases in plasma
glucagon. This proposal was consistent with a previous report that
showed that acute declines in blood glucose concentrations (induced
by insulin), even under hyperglycemic conditions, induced glucagon
secretion in patients with type 2 diabetes [34]. Importantly, dapagli-
ﬂozin increased glucagon secretion only in diabetic mice, not in control8 MOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. Tmice; probably because the effects of SGLT2 inhibitors were
augmented under diabetic conditions.
Our interpretation for the results of Figure 1 is as follows; 10 mg/kg
dapagliﬂozin had more urinary glucose excretion than 10 mg/kg
canagliﬂozin (Figure 1C). However, 10 mg/kg dapagliﬂozin also
increased plasma glucagon (Figure 1D), which might have partly offset
the blood glucose lowering effect induced by urinary glucose excretion
(Figure 1AeB). By contrast, because 10 mg/kg canagliﬂozin did not
increase plasma glucagon (Figure 1D), blood glucose levels were
directly affected by the urinary glucose excretion (Figure 1AeC). We
summarized these observations in Supplementary Figure 2.
Intriguingly, canagliﬂozin did not increase plasma glucagon levels,
even though canagliﬂozin and dapagliﬂozin reduced blood glucose and
increased urinary glucose excretion to the same extents. We consid-
ered that it was unlikely that a secondary suppression of glucagon was
mediated by insulin [7] or GLP-1 [35,36], because canagliﬂozin
appeared to reduce plasma insulin levels and it did not alter the active
GLP-1 levels (Figure 1E,F). A previous study showed that canagliﬂozin
increased “postprandial” plasma GLP-1 levels [37]. On the other hand,his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: Increased SGLT1, decreased GLUT1 mRNA levels in the islets of HFHSD mice and db/db mice, compared to control mice. (A) Relative SGLT1 and GLUT1 mRNA
expression in aTC1 cells cultured with 5, 11, 18, or 25 mM glucose for 48 h (n ¼ 3 per group). (B) Relative SGLT1 and GLUT1 mRNA expression in islets from mice fed NC (n ¼ 6)
or HFHSD (n ¼ 13), at the age of 22-weeks. (C) Relative SGLT1 and GLUT1 mRNA expression in islets from non-diabetic controls (db/þ) or diabetic (db/db) mice, at the age of 16-
weeks (n ¼ 4). (D) Glucagon secretion from islets of NC or HFHSD mice in 5 mM glucose conditions (n ¼ 8e9). (E) Glucagon secretion from islets of db/þ or db/db mice (n ¼ 6).
(F) Glucagon secretion from islets incubated with or without 20 mM sotagliﬂozin or 300 mM phloretin (n ¼ 9e10). (G) Relative SGLT1 mRNA expression (n ¼ 10) or glucagon
secretion (n ¼ 11) in mouse islets transfected with SGLT1 siRNAs or scrambled siRNA. Data are the mean  SE relative to controls or the mean  SE percentage of control group
values. *p < 0.05, **p < 0.01; vs. respective control.a recent report showed that the oral administration of canagliﬂozin
enhanced GLP-1 secretion by increasing the glucose delivery to lower
part of the small intestine. Moreover, in this report canagliﬂozin
showed no direct effect on GLP-1 release in vitro [38]. Because food
was removed from the cages before drug administration in our
experiment, canagliﬂozin might not have increased plasma active GLP-
1 levels.MOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. This is an open acc
www.molecularmetabolism.comBecause we showed that canagliﬂozin (but not dapagliﬂozin) sup-
pressed glucagon secretion in aTC1 cells by inhibiting SGLT1, we
suspect that the compensatory increase in glucagon secretion might
have been canceled due to the direct suppression of glucagon secretion
by canagliﬂozin. This idea might be partly supported by the recent report
that SGLT1 knockout mice did not increase plasma glucagon levels even
under the glucagon increasing conditions in control mice [39]. Iness article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Original Articleaddition, a recent clinical trial showed that canagliﬂozin treatment did
not increase plasma glucagon in T2DM patients [40].
The issue of whether a clinical dose of canagliﬂozin might inhibit
SGLT1 in a cells in vivo, remains under debate. First, consider the
effective concentration produced with a 300 mg dose of canagliﬂozin,
which is a clinical daily dose. This dose was reported to produce a
peak plasma concentration of 7.8e10 mM in humans [26,31]. How-
ever, w98% of canagliﬂozin binds to plasma proteins [26], which
results in a free canagliﬂozin concentration of 156e200 nM in plasma.
This effective concentration is below the IC50 (684e710 nM) of can-
agliﬂozin for SGLT1 inhibition in humans [26]. Therefore, it remains
unclear whether a clinical dose of canagliﬂozin would inhibit SGLT1 in
a cells, when administered in patients. On the other hand, the
selectivity of dapagliﬂozin for SGLT2 is much higher than that of
canagliﬂozin. Thus, a clinical dose of dapagliﬂozin would be unlikely to
inhibit SGLT1, and thus, dapagliﬂozin would not be expected to affect
glucagon secretion in a cells.
We showed that canagliﬂozin suppression of glucagon secretion
depended on glucose transport, but not on glucose metabolism. These
results indicated that the inﬂux of a SGLT substrate (probably Naþ)
through SGLT1 was associated with glucagon secretion. This mech-
anism was reminiscent of one previously described regarding GLP-1
secretion in intestinal L cells. The mechanism for GLP-1 secretion
via SGLT1 was proposed as follows; an increased inﬂux of SGLT
substrates generated an inward current, which depolarized the
membrane and stimulated Ca2þ entry [20e24]. This same mechanism
could be applicable to glucagon secretion in a cells. Actually, we
showed that non-metabolizable SGLTs speciﬁc substrate aMG
increased [Ca2þ]i in aTC1 cells (Figure 6A), suggesting that a inﬂux of
SGLT1 substrates could be associated with glucagon secretion. It was
also reported that SGLT1 acted as the luminal glucose sensor in L cells,
even though the intracellular glucose concentration was largely
determined by GLUT activity [21].
We showed that SGLT1 was predominantly expressed in the a cells of
mouse islets and human islets (Figure 2D,E), and the SGLT1 mRNA
levels were likely correlated with the levels of glucagon secretion
(Figure 7AeG). Interestingly, we found that SGLT1 and GLUT1 mRNA
displayed opposite expression patterns in the islets of HFHSD mice and
db/db mice. Furthermore, when SGLT1 was inhibited by sotagliﬂozin,
glucagon secretion was suppressed, but when GLUT1 was inhibited by
phloretin, glucagon secretion was enhanced in mouse islets. This result
suggested that SGLT1 and GLUT1 might contribute to the regulation of
glucagon secretion with opposing signals. Considering that SGLT1
mRNA levels in a cells was elevated under high glucose and diabetic
conditions, and that elevated SGLT1 mRNA levels was associated with
increased glucagon secretion, we suggest that increased SGLT1
expression in a cells might represent an etiology of hyperglucagonemia
observed in the patients of type 2 diabetes. However, further studies will
be needed to elucidate this important issue.
Finally, our ﬁndings had some clinical implications. First, because
clinical trials have shown that both canagliﬂozin and dapagliﬂozin
improved clinical outcomes in patients with type 2 diabetes [40e44], it
remains unclear whether the different effects on glucagon secretion
might be clinically relevant in diabetes therapy. On the other hand,
SGLT2 inhibitors were also expected to be applicable to cancer therapy
[45,46] and nonalcoholic fatty liver disease treatments [47]. Consid-
ering that glucagon can affect the growth of cancer cells [48e50], and
that nonalcoholic fatty liver disease is often accompanied by fasting
hyperglucagonemia [51], glucagon might be related to the patho-
physiology of those diseases. Thus, we expect that the results of the
present study might have important implications for the classiﬁcation10 MOLECULAR METABOLISM- (2018) 1e12  2018 The Authors. Published by Elsevier GmbH. Tand selection of SGLT2 inhibitors in the treatment of various diseases,
in addition to diabetes.
5. CONCLUSIONS
Our results suggest that a novel mechanism regulated glucagon
secretion through SGLT1 in a cells. This ﬁnding possibly explained the
distinct effects of dapagliﬂozin and canagliﬂozin on plasma glucagon
levels in mice, and might provide implications for the classiﬁcation and
selection of SGLT2 inhibitors in the treatment of diabetes. Moreover,
SGLT1 in a cells might contribute to the mechanism underlying
hyperglucagonemia in diabetic patients, which requires further
research in order to be elucidated.
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